Porphyria cutanea tarda: A possible role for ascorbic acid

Hepatology

Volumn 45, Issue 1, 2007, Pages 6-8

  Anderson, Karl E ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CHLOROQUINE; HYDROXYCHLOROQUINE; IRON DEXTRAN; UROPORPHYRINOGEN; UROPORPHYRINOGEN DECARBOXYLASE;

CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG POTENTIATION; EDITORIAL; EPIDEMIC; GENE MUTATION; HUMAN; IRON DEFICIENCY; LIVER CELL; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PHLEBOTOMY; PHOTOSENSITIVITY; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; TREATMENT PLANNING; TURKEY (BIRD);

ANIMALS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; DISEASE SUSCEPTIBILITY; DOWN-REGULATION; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; PORPHYRIA CUTANEA TARDA; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 33846455400     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21514     Document Type: Editorial

References (25)

1. Anderson KE. The porphyrias (Chapter 72). In: Boyer T, Wright T, Manns M, eds. Zakim and Boyer's Hepatology: A Textbook of Liver Diseases, Philadelphia, PA: Elsevier; 2006:1391-1432.
2. Elder GH. Porphyria cutanea tarda and related disorders. In: Kadish KM, Smith K, Guilard R, eds. Porphyrin Handbook, Part II. Vol. 14. San Diego, CA: Academic Press, 2003:67-92.
3. Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419-426.
4. Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol 1988;29:3-7.
5. Schmid R. Cutaneous porphyria in Turkey. N Engl J Med 1960;263:397-398.
6. Phillips JD, Jackson LK, Bunting M, Franklin MR, Thomas KR, Levy JE, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 2001;98:259-264.
7. Sinclair PR, Gorman N, Dalton T, Walton HS, Bernent WJ, Sinclair JF, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J 1998;330: 149-153.
8. Sinclair PR, Gorman N, Walton HS, Bernent WJ, Szakacs J, Gonzalez FJ, et al. Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone. Arch Biochem Biophys 2000;384:383-390.
9. Sinclair PR, Gorman N, Walton HS, Bernent WJ, Dalton TP, Sinclair JF, et al. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000;162:60-67.
10. Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, et al. Protection of the Cyp1A2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2001;173:89-98.
11. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003;30:137-144.
12. Smith A. Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer. In: Kadish KM, Smith K, Guilard R, eds. Porphyrin Handbook, Part II. Vol. 14. San Diego, CA: Academic Press, 2003:169-210.
13. Elder GH, Urquhart AJ, de Salamanca RE, Munoz JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1985;2:229-233.
14. Percy VA, Naidoo D, Joubert SM, Pegoraro RJ. Ascorbate status of patients with porphyria cutanea tarda symptomatica and its effect on porphyrin metabolism. S Afr J Med Sci 1975;40:185-196.
15. Sinclair PR, Gorman G, Shedlotsky SI, Honsinger C, Sinclair JF, Karagas MR, et al. Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 1997;130:197-201.
16. Rocchi E, Casalgrandi G, Masini A, Giovannini F, Ceccarelli D, Ferrali M, et al. Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders. Ital J Gastroenterol Hepatol 1999;31:861-867.
17. Gorman N, Zaharia A, Trask HS, Szakacs JG, Jacobs NJ, Jacobs JM, et al. Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda. HEPATOLOGY 2007;45:187-194.
18. Sinclair PR, Gorman N, Walton HS, Bernent WJ, Jacobs JM, Sinclair JF. Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation. Arch Biochem Biophys 1993;304:464-470.
19. Sinclair PR, Gorman N, Sinclair JF, Walton HS, Bernent WJ, Lambrecht RW. Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats. HEPATOLOGY 1995;22:565-572.
20. Taljaard JJF, Shanley BC, Stewart-Wynne EG, Deppe WM, Joubert SM. Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol 1972;87:261-269.
21. Ashton RE, Hawk JLM, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1984;3:609-613.
22. Bulaj ZJ, Franklin MR, Phillips JD, Miller KL, Bergonia HA, Ajioka RS, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000;136:482-488.
23. Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, et al. Hepatitis-C virus and porphyria cutanea tarda-evidence of a strong association. HEPATOLOGY 1992;16:1322-1326.
24. Berk PD. An editor's look-back. HEPATOLOGY 2006;43(Suppl 1):S13-S30.
25. Christiansen L, Bygum A, Jensen A, Thomsen K, Brandrup F, Horder M, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 2000;107:612-614.